INFORMATION BY CANCER TYPE
David McDermott, M.D. discusses new advances made to treat kidney cancer.
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Three recent trials showed that Keytruda had a durable response for patients with a rare subtype of melanoma.
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Roy Herbst, M.D., Ph.D., spoke with CURE about the future of Keytruda, and immunotherapy in general, to treat lung cancer.
Immunotherapy agents have their own set of side effects, and managing them quickly and efficiently is key.
How and why I've chosen to live my cancer in the public eye.
Growing scientific insights have led to the swift development of treatments for advanced melanoma, leaving doctors to iron out details about their application.
The role of immunotherapies and targeted treatments in lung cancer is evolving at breakneck speed.